Establishing a US foothold has been on Ipsen chairman and CEO Jean-Luc Bélingard’s to-do list almost since his arrival in 2002 at what was then a privately-owned, family-run French drug firm.
Now he can tick that item off—at least partly. In July 2006, Ipsen announced a tie-up with US biotech Tercica...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?